Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 4/20 | 0.44 |
| ▸ | PGK2 | P07205 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9112987 | 0.83 | FFAR1 (0.44) | FFAR1FFAR4 | |
| SCHEMBL9512450 | 0.81 | HDAC1 (0.43) | ENPP2DGAT2FFAR1SRC | |
| SCHEMBL5692310 | 0.80 | ALDH1A1 (0.44) | FFAR1FFAR4 | |
| SCHEMBL9181038 | 0.80 | PGK1 (0.46) | PGK1PGK2 | |
| SCHEMBL9445925 | 0.79 | PGK1 (0.44) | ENPP2DGAT2PGK1PGK2 | |
| SCHEMBL12311041 | 0.78 | ENPP2 (0.53) | ENPP2DGAT2PGK1PGK2SRC | |
| SCHEMBL157472 | 0.78 | CA2 (0.50) | — | |
| SCHEMBL8468352 | 0.77 | FFAR1 (0.43) | FFAR1FFAR4 | |
| SCHEMBL13611310 | 0.77 | FFAR1 (0.59) | FFAR1 | |
| Hydrochloric Acid SCHEMBL11841695 | 0.76 | CA1 (0.44) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009526755-A | — | — | 2009-07-23 | — | — | JP | claimed |
| EP-1979366-A2 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | Yu, Ruey J. (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007082206-A2 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J (US) | 2007-07-19 | — | — | WO | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0313002-B1 | Phenyl glycines for use in reducing neurotoxic injury | SEARLE & CO (US) | 1993-12-01 | — | — | EP | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| US-4918064-A | TREATMENT OF ANOXIA OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-04-17 | — | — | US | claimed |
| EP-0313002-A2 | Phenyl glycines for use in reducing neurotoxic injury | G.D. Searle & Co. (US) | 1989-04-26 | — | — | EP | claimed |
| JP-1135790-A | — | — | None | — | — | JP | disclosed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-0364996-A2 | Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury | G.D. Searle & Co. (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4918064-A | TREATMENT OF ANOXIA OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-04-17 | — | — | US | disclosed |
| JP-H01135790-A | PHENYL GLYCINE DERIVATIVE | G D SEARLE & CO | 1989-05-29 | — | — | JP | disclosed |
| EP-0313002-A2 | Phenyl glycines for use in reducing neurotoxic injury | G.D. Searle & Co. (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | ENPP2 821/4885DGAT2 3033/4885PGK1 1994/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | ENPP2 821/4885DGAT2 3033/4885PGK1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.